Latest & greatest articles for insulin

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on insulin or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on insulin and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for insulin

1001. Oral and buccal insulin for diabetes - horizon scanning review

Oral and buccal insulin for diabetes - horizon scanning review Oral and buccal insulin for diabetes - horizon scanning review Oral and buccal insulin for diabetes - horizon scanning review NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Oral and buccal insulin for diabetes - horizon scanning review. Birmingham: National Horizon (...) Scanning Centre (NHSC). New and Emerging Technology Briefing. 2001 Authors' objectives To summarise the current research evidence on oral and buccal insulin for diabetes. Authors' conclusions One buccal and three oral formulations of insulin are known to be in clinical development. There is no information on equivalence to injected insulin, long-term benefits or cost at the present time - Clinical impact: The use of oral/buccal insulin is an innovative development that may impact on the quality of life

2001 Health Technology Assessment (HTA) Database.

1002. [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness]

[Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness] Conversion de la terapia intensiva con insulina rapida a insulina lispro en la diabetes tipo 1: analisis farmacoeconomico de coste-efectividad [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness] Conversion de la terapia intensiva con insulina rapida a insulina lispro en la diabetes (...) tipo 1: analisis farmacoeconomico de coste-efectividad [Conversion of fast insulin intensive therapy to lispro insulin in type I diabetes: pharmacoeconomic analysis of cost-effectiveness] Costa Pinel B, Belmonte Serrano M, Paez Vives F, Sabate Obiol A, Estopa Sanchez A, Borras Borras J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed

2001 NHS Economic Evaluation Database.

1003. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. (Abstract)

Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Effective glycaemic control in type 1 diabetes mellitus usually requires two or more insulin injections daily. Inhaled intrapulmonary delivery of insulin offers a potential new way to deliver meal-related insulin, eliminating the need for preprandial injections.73 patients with type 1 diabetes mellitus were studied in an open-label, proof-of-concept, parallel-group randomised trial. Patients (...) in the experimental group received preprandial inhaled insulin plus a bedtime subcutaneous ultralente insulin injection. Patients in the control group received their usual insulin regimen of two to three injections per day. Participants monitored their blood glucose four times daily, and adjusted insulin doses weekly to achieve preprandial glucose targets of 5.6-8.9 mmol/L. The primary outcome measure was change in glycosylated haemoglobin (HbA1c) after 12 weeks. Secondary outcomes were fasting and postprandial

2001 Lancet Controlled trial quality: uncertain

1004. Intensive Insulin Therapy in Critically Ill Patients

Intensive Insulin Therapy in Critically Ill Patients PEDSCCM.org Criteria abstracted from series in Review Posted: founded 1995 Questions or comments?

2001 PedsCCM Evidence-Based Journal Club

1005. Lantus (Insulin Glargine [rDNA Origin]) Injection

Lantus (Insulin Glargine [rDNA Origin]) Injection Drug Approval Package: Lantus (Insulin Glargine [rDNA Origin]) NDA #21-081 Drug Approval Package U.S. Food & Drug Administration Search FDA Drug Approval Package - Lantus (Insulin Glargine [rDNA Origin]) Injection Company: Aventis Pharmaceuticals Inc. Application No.: 21-081 Approval Date: 4/20/2000 (PDF) (PDF) (PDF) (PDF) (PDF) Pharmacology Review(s) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Correspondence (PDF) (PDF) Date created: November 20, 2001

2000 FDA - Drug Approval Package

1006. Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared

Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared Hypoglycaemia induced by exogenous insulin - 'human' and animal insulin compared Airey C M, Williams D R, Martin P G, Bennett C M, Spoor P A Authors' objectives To compare the effects of 'human' and animal insulin on the frequency and awareness of hypoglycaemia. Searching MEDLINE (from 1975 to February 1999), EMBASE, HealthPLAN (...) Randomised controlled trials (RCTs), other comparative studies, and case series and case reports were eligible for inclusion. The studies could be of any duration. Specific interventions included in the review Studies that compared human insulin with animal insulin were eligible for inclusion. The review used the term 'human' to cover insulins produced by enzymatic modification of porcine insulin, or recombinant DNA technology. The studies could use any type of insulin in any dosage regimen. Population

2000 DARE.

1007. Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study

Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Cost-effectiveness of intensive insulin therapy for type 2 diabetes: a 10-year follow-up of the Kumamoto study Wake N, Hisashige A, Katayama T, Kishikawa H, Ohkubo Y, Sakai M, Araki E, Shichiri M Record Status This is a critical abstract of an economic evaluation that meets (...) the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Intensive insulin therapy for type 2 diabetes in Japan. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population The study population consisted of Japanese patients with type 2 diabetes. Setting The setting was a hospital

2000 NHS Economic Evaluation Database.

1008. Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients

Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients Pons JM Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pons JM (...) . Continuous subcutaneous infusion of insulin with portable pump in diabetes type 1 patients. Barcelona: Catalan Agency for Health Information, Assessment and Quality (CAHIAQ -formerly CAHTA). IN01/2000. 2000 Authors' objectives To review the available evidence on continuous subcutaneous infusion of insulin with portable pump in diabetes type I patients. Authors' conclusions Continuous subcutaneous external infusion insulin pumps were found to be effective to achieve good metabolic control, the closest

2000 Health Technology Assessment (HTA) Database.

1009. Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report)

Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Amate Blanco J M, Van den Eynde A M, Saz Z, Conde Olasagasti J L Record Status This is a bibliographic record of a published health technology assessment from (...) a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Amate Blanco J M, Van den Eynde A M, Saz Z, Conde Olasagasti J L. Efficacy of insulin infusion pumps. Impact on the quality of life of certain patients. IPE-00/27 (Public report) Madrid: Agencia de Evaluacion de Tecnologias Sanitarias (AETS). Informe de Evaluacion de Tecnologias Sanitarias No.27. 2000 Authors' objectives The goal of this report is to evaluate the efficacy of insulin infusion

2000 Health Technology Assessment (HTA) Database.

1010. Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: results from the DIGAMI study

Cost-effectiveness of intense insulin treatment after acute myocardial infarction in patients with diabetes mellitus: results from the DIGAMI study Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2000 NHS Economic Evaluation Database.

1011. Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial

Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial Telecare of diabetic patients with intensified insulin therapy: a randomized clinical trial Biermann E, Dietrich W, Standl E Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results (...) and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The technology studied was a telecare system for the monitoring and revision of insulin therapy. Patients transmitted their blood glucose readings to a diabetes centre using a modem interface. A physician then revised insulin treatment during scheduled telephone consultations with patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

2000 NHS Economic Evaluation Database.

1012. Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. (Abstract)

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group. Oral administration of autoantigens can slow the progression of beta-cell destruction in non-obese diabetic mice. We investigated whether oral administration of recombinant human insulin could protect residual beta-cell function in recent-onset type 1 diabetes.We enrolled 131 autoantibody-positive diabetic patients aged 7-40 years (...) within 2 weeks of diagnosis (no ketoacidosis at diagnosis, weight loss <10%, polyuria for <6 weeks). They were randomly assigned 2.5 mg or 7.5 mg oral insulin daily or placebo for 1 year, in addition to subcutaneous insulin therapy. Serum C-peptide concentrations were measured in the fasting state and after stimulation, to assess beta-cell function. Autoantibodies to beta-cell antigens were assayed. Analyses were by intention to treat.Baseline C-peptide and haemoglobin A1c concentrations were similar

2000 Lancet Controlled trial quality: predicted high

1013. A comparison of glyburide and insulin in women with gestational diabetes mellitus. (Abstract)

A comparison of glyburide and insulin in women with gestational diabetes mellitus. Women with gestational diabetes mellitus are rarely treated with a sulfonylurea drug, because of concern about teratogenicity and neonatal hypoglycemia. There is little information about the efficacy of these drugs in this group of women.We studied 404 women with singleton pregnancies and gestational diabetes that required treatment. The women were randomly assigned between 11 and 33 weeks of gestation to receive (...) glyburide or insulin according to an intensified treatment protocol. The primary end point was achievement of the desired level of glycemic control. Secondary end points included maternal and neonatal complications.The mean (+/-SD) pretreatment blood glucose concentration as measured at home for one week was 114+/-19 mg per deciliter (6.4+/-1.1 mmol per liter) in the glyburide group and 116+/-22 mg per deciliter (6.5+/-1.2 mmol per liter) in the insulin group (P=0.33). The mean concentrations during

2000 NEJM Controlled trial quality: uncertain

1014. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. Full Text available with Trip Pro

Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. To assess and compare the effects of candesartan or lisinopril, or both, on blood pressure and urinary albumin excretion in patients with microalbuminuria, hypertension, and type 2 diabetes.Prospective, randomised, parallel group, double blind study with four week placebo run

2000 BMJ Controlled trial quality: predicted high

1015. Insulin lispro: a critical evaluation

Insulin lispro: a critical evaluation Insulin lispro: a critical evaluation Insulin lispro: a critical evaluation Shukla VK, Otten N Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Shukla VK, Otten N. Insulin lispro: a critical evaluation. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA). Technology Report (...) Issue 5. 1999 Authors' objectives To summarise the evidence relating to the effectiveness and cost effectiveness of insulin lispro. Authors' conclusions The reported advantages of lispro are: It lessens the rise in serum glucose after meals. Hypoglycemic episodes occur less frequently. The overall glycemic control is improved in patients with type I diabetes who require insulin pumps. It has been proposed that lispro would be of benefit to patients with unpredictable mealtimes to allow more schedule

1999 Health Technology Assessment (HTA) Database.

1016. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. (Abstract)

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. Treatment with diet alone, insulin, sulfonylurea, or metformin is known to improve glycemia in patients with type 2 diabetes mellitus, but which treatment most frequently attains target fasting plasma glucose (FPG) concentration of less than 7.8 mmol/L (140 mg/dL) or glycosylated (...) a median (interquartile range) FPG concentration of 11.5 (9.0-14.4) mmol/L [207 (162-259) mg/dL], HbA1c levels of 9.1% (7.5%-10.7%), and a mean (SD) body mass index of 29 (6) kg/m2.After 3 months on a low-fat, high-carbohydrate, high-fiber diet, patients were randomized to therapy with diet alone, insulin, sulfonylurea, or metformin.Fasting plasma glucose and HbA1c levels, and the proportion of patients who achieved target levels below 7% HbA1c or less than 7.8 mmol/L (140 mg/dL) FPG at 3, 6, or 9

1999 JAMA Controlled trial quality: uncertain

1017. Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. Full Text available with Trip Pro

Twice daily versus four times daily insulin dose regimens for diabetes in pregnancy: randomised controlled trial. To compare perinatal outcome and glycaemic control in two groups of pregnant diabetic patients receiving two insulin regimens.Randomised controlled open label study.University affiliated hospital, Israel.138 patients with gestational diabetes mellitus and 58 patients with pregestational diabetes mellitus received insulin four times daily, and 136 patients with gestational diabetes (...) and 60 patients with pregestational diabetes received insulin twice daily.Three doses of regular insulin before meals and an intermediate insulin dose before bedtime (four times daily regimen), and a combination of regular and intermediate insulin in the morning and evening (twice daily regimen).Maternal glycaemic control and perinatal outcome.Mean daily insulin concentration before birth was higher in the women receiving insulin four times daily compared with twice daily: by 22 units (95% confidence

1999 BMJ Controlled trial quality: predicted high

1018. Improvement of insulin sensitivity by short-term exercise training in hypertensive African American women. (Abstract)

Improvement of insulin sensitivity by short-term exercise training in hypertensive African American women. African American women have a high prevalence of insulin resistance, non-insulin-dependent diabetes mellitus, obesity, and hypertension that may be linked to low levels of physical activity. We sought to determine whether 7 days of aerobic exercise improved glucose and insulin metabolism in 12 obese (body fat >35%), hypertensive (systolic blood pressure > or =140 and/or diastolic blood (...) pressure > or =90 mmHg) African American women (mean age 51+/-8 years). Insulin-assisted frequently-sampled intravenous glucose tolerance tests were performed at baseline and 14 to 18 hours after the 7th exercise session. There was no significant change in maximal oxygen consumption, body composition, or body weight after the 7 days of aerobic exercise. The insulin sensitivity index increased (2.68+/-0.45 x 10[-5] to 4.23+/-0.10 x 10[-5] [min(-1)/pmol/L], P=.02). Fasting (73+/-9 to 50+/-9 pmol/L, P=.02

1998 Hypertension (Dallas, Tex. : 1979)

1019. Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus

Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus Cost-effectiveness of the primary prevention of non-insulin dependent diabetes mellitus Segal L, Dalton A C, Richardson J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions (...) followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Programmes for the primary prevention of non-insulin dependent diabetes mellitus (NIDDM). Type of intervention Primary prevention. Economic study type Cost-effectiveness analysis. Study population The study targeted selected groups including persons with IGT, overweightese men, seriously obese persons, women with previous gestational diabetes and the general population. Setting

1998 NHS Economic Evaluation Database.

1020. Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management

Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Penfornis A, Millot L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Outpatient approach to initiating insulin therapy in insulin-requiring Type 2 diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Type 2 diabetic patients

1998 NHS Economic Evaluation Database.